<th id="8ilbc"><pre id="8ilbc"></pre></th>
<button id="8ilbc"><acronym id="8ilbc"></acronym></button>

<span id="8ilbc"><pre id="8ilbc"><sup id="8ilbc"></sup></pre></span><dd id="8ilbc"><noscript id="8ilbc"></noscript></dd>
<th id="8ilbc"><track id="8ilbc"></track></th>

  • <button id="8ilbc"><object id="8ilbc"></object></button>

    <em id="8ilbc"></em>
  • <em id="8ilbc"><ruby id="8ilbc"><input id="8ilbc"></input></ruby></em>

        <em id="8ilbc"><ruby id="8ilbc"><input id="8ilbc"></input></ruby></em>
        Pipeline: Ciforadenant (CPI-444)

        Antagonist of adenosine A2A receptor

        Indications:Renal cancer and Multiple myeloma

        Ciforadenant is one of our main projects and is an oral small molecule antagonist of the adenosine A2A receptor. By precisely targeting and blocking A2A receptors on immune cells, ciforadenant may unleash their cancer-killing properties.

        Ciforadenant is designed to block adenosine in the tumor microenvironment to bind to A2A receptors, so that the tumor lose the function of avoiding the attack by the immune system. Results from several pre-clinical models and human clinical trials have demonstrated that ciforadenant was active alone in patients with some cancers. Pre-clinical research results have been published in some famous journals and Clinical data have been presented at several conferences, including American Society of Clinical Oncology, American Cancer Research Association and Cancer Immunotherapy Association.


        Pipeline:CPI-006

        Anti-CD73Inhibitor of Adenosine production, anti-CD73 antibody

        Indications:Solid tumors

        CPI-006 is a humanized anti-73 monoclonal antibody. Unlike most antibodies, CPI-006 is a designed smart antibody and has other distinct properties: to enhance the activity and trafficking capacity of immune cells, to further reduce the destructive capabilities of cancer cells.

        CPI-006 binds to CD73 and appears to inhibit production of immunosuppressive adenosine of tumor cells. It also acts on other important immune procedures.


        Pipeline:CPI-818

        ITK Inhibitor

        Indications:T cell lymphoma and Autoimmune lymphoproliferative disorders

        CPI-818 is an oral, small molecule drug and selectively inhibits ITK (interleukin-2-inducible T cell kinase). ITK is an enzyme expressed predominantly in T cells and that plays a role in T cell and natural killer (NK) cell lymphomas and leukemias, as well as in normal immune function.

        Our CPI-818 has dual properties: to block malignant T cell growth, and to modulate immune responses. We believe inhibiting ITK may be of therapeutic benefit for patients with T-cell lymphomas, certain B cell lymphomas and those with solid tumors because of its potential immune-enhancing properties.

        Pipeline:CPI-818

        ITK Inhibitor

        Indications:T cell lymphoma and Autoimmune lymphoproliferative disorders

        CPI-818 is an oral, small molecule drug and selectively inhibits ITK (interleukin-2-inducible T cell kinase). ITK is an enzyme expressed predominantly in T cells and that plays a role in T cell and natural killer (NK) cell lymphomas and leukemias, as well as in normal immune function.

        Our CPI-818 has dual properties: to block malignant T cell growth, and to modulate immune responses. We believe inhibiting ITK may be of therapeutic benefit for patients with T-cell lymphomas, certain B cell lymphomas and those with solid tumors because of its potential immune-enhancing properties.

        91视频久久久_亚洲欧美18岁网站_久久97超碰国产精品_亚洲 欧洲 日韩 综合在线